Carlos González

/Tag:Carlos González
­

Ojer Pharma and Bionaturis sign a registration and commercialization agreement to market MUPIPET® in Europe

Ojer Pharma and Bionaturis have signed a co-development, registration, and commercialization agreement to market Mupipet® in Europe, the first antibiotic with a bioadhesive and transparent formulation registered in Europe to treat skin bacterial infections in companion animals.

Mupipet® will be registered as a prescription veterinary drug for the topical treatment of skin bacterial infections in companion animals -such as pyoderma- being its main competitive advantage its cutting-edge formulation, developed and patented by the pharmaceutical company Ojer Pharma. Mupipet® is formulated in a transparent bioadhesive film, with acts as a controlled release matrix, ensuring the permanence of the active substance at the site of action and, as a result, a higher efficacy. This system makes unnecessary the use of dressing pads to cover the affected area and reduces product removal accidentally or by scratching and licking, which allows the treatment permanence for at least 12 hours. “The results of field studies already performed demonstrate that Mupipet® has better safety and efficacy profile that other reference products”, Carlos Gonzalez, General Manager at Ojer Pharma, has stated. “The isolation provided by this bioadhesive lipogel formulation reduces the risk of infections and protects the skin against external agents, as well as ensures the permanence of the product in the skin until the infection has been completely removed, with an excellent skin tolerability and non-irritant”, he has added.

“With this agreement, Mupipet® enriches our Premium portfolio for pets, in this case, under the category of prescription drugs. Due to its features, Mupipet® is a unique patent-protected product with outstanding competitive advantages versus other alternatives, and fitting our portfolio requirements. Besides, we expect this strategic agreement consolidates the relationship with Ojer Pharma to start the development of new innovative products. The transparent bioadhesive […]

March 29th, 2017|Blog english|Comments Off on Ojer Pharma and Bionaturis sign a registration and commercialization agreement to market MUPIPET® in Europe

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR